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Abstract
Tight glycaemic control emerged on the scene of critical care in
2001. Surprisingly, not many confirmation trials have been
published so far. The randomised controlled trial by De La Rosa
and colleagues is a timely and valuable attempt to repeat the
landmark Leuven studies. The failure to replicate the beneficial
effects of tight glycaemic control may boil down to some less
obvious defaults in the set-up of the trial despite a seemingly
adequate study design. The incorporation of ample power
calculations and strict adherence to glucose targets are essential
to fairly compare studies on tight blood glucose control. Only if
these basic conditions of study design are fulfilled can the
effectiveness of the therapy be assessed.
The study of De La Rosa and colleagues [1] is the first
published randomised controlled trial set up to test whether
tight glycaemic control in a mixed medical-surgical intensive
care unit (ICU) population is beneficial. The proof-of-concept
work by Van den Berghe and colleagues [2] in Leuven
showed, in two separate single-centre studies, that lowering
blood glucose levels to 80 to 110 mg/dL (4.4 to 6.1 mM),
compared with a strategy in which insulinisation is started
only when blood glucose levels exceeded 180 mg/dL
(10 mM), improved the outcome in a surgical [2] as well as in
a medical [3] ICU patient population. The trial of De La Rosa
and colleagues did not confirm the results from these seminal
Leuven studies.
To unravel the roots of the discrepancy between the results,
the basic principles of evidence-based medicine may be a
helpful guide. Foremost, a relevant clinical question leads to
the study hypothesis, which ought to be reflected in the study
design. In this regard, De La Rosa and colleagues should be
congratulated that the question whether tight glycaemic
control truly works in a mixed ICU population resulted in a
randomised controlled study design. This is a major step-up
over implementation studies, which showed a benefit of tight
glycaemic control but are substandard to assess effective-
ness of a therapy [4]. The overall methodological quality was
adequate with regard to randomisation, allocation conceal-
ment, intention-to-treat analysis, and completeness of follow-
up. The slight differences in study population, such as the
proportion of patients post-cardiac surgery and the on-
admission APACHE (Acute Physiology and Chronic Health
Evaluation) II score, are probably of minor importance. The
pitfalls that matter may hide beneath the surface.
First, the primary outcome in the trial of De La Rosa and
colleagues was 28-day mortality. Although this is a clear-cut
and hard endpoint, it may not be the most appropriate. As
tight glycaemic control is a preventative strategy against ICU
complications such as infections, prolonged weaning, and
ultimately death, benefit can be expected only if patients
remain in the ICU for at least a week. The Kaplan-Meier plots
of the hospital survival in the trials of Van den Berghe and
colleagues start to diverge only around day 25 and the follow-
up extended well over 100 days. Alternatively, the 90-day
mortality, which is being used in the NICE-SUGAR (Normo-
glycaemia in Intensive Care Evaluation and Survival Using
Glucose Algorithm Regulation) multi-centre trial, may have
been better [5].
Second, the study was predestined to capsize as the power
calculation drew on an unrealistic absolute risk reduction of
10% in the 28-day mortality. It is now known from the Leuven
studies that at most a 4% absolute risk reduction in the
intention-to-treat population can be expected in the surgical
as well as in the medical ICU population [6]. Consequently,
the study was already vastly underpowered to start with,
aiming to recruit only 504 patients. The combined Leuven
population, in hindsight also underpowered in the intention-
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to-treat analysis, included 2,748 patients. To address this
issue, the NICE-SUGAR trial has just stopped after having
recruited 6,100 patients [5].
Third, further aggravating the problem of power, the study
turned out to realize intensive insulin therapy, but without tight
glycaemic control. The median morning blood glucose level in
the intensive treatment group was 120 mg/dL (6.7 mM),
which is higher than the preset target of 80 to 110 mg/dL
(4.4 to 6.1 mM). As a result, only 39.4% of the patients in the
intensive treatment groups remained within range for their
entire ICU stay, whereas in the Leuven studies this was over
70%. Of minor importance, in the standard group, the authors
aimed to maintain blood glucose levels of between 180 to
200 mg/dL (10 to 11.1 mM), but expectedly the median
morning blood glucose level drifted to 148 mg/dL (8.2 mM),
with only 17.2% of the patients in range. Such a deviation
points to protocol violations or a learning curve in the blood
glucose control or a combination of the two. The resulting
overlap of about 50% between the standard and intensive
treatment groups weakened the robustness of the results of
the study. It also makes it impossible to gauge an effect size,
let alone to decisively judge the effectiveness of tight
glycaemic control.
The honest conclusion from this study is that tight glycaemic
control is a demanding and complex intervention, making it
hard to steer blood glucose levels in the right stratum. For
these complex interventions, exploratory trials (in this case,
the Leuven studies) should be followed by an adequately
controlled and powered study to assess replicability and
finally by long-term implementation studies, testing effective-
ness in uncontrolled settings [7].
To put everything into perspective, it is important to point out
that insulin was discovered in 1921. Now, well after 80 years,
the scientific and clinical endocrine community is still unsure
about the right targets in glycaemic management [8,9].
Hence, we ought to be very careful not to thwart the concept
of blood glucose control in the critically ill patient before
giving it a fair chance in properly executed confirmation trials.
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